Navigation Links
ULURU Inc. Receives Letter of Non-Compliance From NYSE Amex
Date:3/11/2011

ADDISON, Texas, March 11, 2011 /PRNewswire/ -- ULURUInc.(NYSE Amex: ULU), a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, today reported that it has received notice from NYSE Amex LLC (the "Exchange") advising ULURU that it is not in compliance with a certain condition of the Exchange's continued listing standards under Section 1003 of the Exchange's Company Guide (the "Company Guide").

In a letter to ULURU, the Exchange stated that it is concerned that ULURU's common stock, as a result of its low selling price, may not be suitable for auction market trading.  Therefore, pursuant to Section 1003(f)(v) of the Company Guide, ULURU's continued listing is predicated on it effecting a reverse stock split of its common stock by no later than June 7, 2011.  As a result of the foregoing, ULURU has become subject to the procedures and requirements of Section 1009 of the Company Guide.

ULURU intends to satisfy the Exchange's continued listing standards by presenting a proposal and resolution to be approved by its shareholders, to effect a reverse stock split of ULURU's common stock, at ULURU's next annual meeting of shareholders to be held no later than June 1, 2011.

AboutULURUInc.:ULURUInc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex™ Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at www.ULURUinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to ULURU's compliance with the continued listing standards of the NYSE Amex, to the risk that a reverse stock split may not result in an actual increase in the market price of our common stock, and to risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, and other reports filed by us with the Securities and Exchange Commission.Contact: CompanyKerry P. GrayPresident&CEOTerry K. WallbergVice President & CFO(214) 905-5145
'/>"/>

SOURCE ULURU Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Announces Agreement With Exciton to Develop Antimicrobial Dressing
2. ULURU Inc. to Raise $500,000 in Registered Direct Offering
3. ULURU Inc. Reports Third Quarter 2010 Financial Results
4. ULURU Inc. Provides Altrazeal® Clinical Update
5. ULURU Inc. Announces Conference Call
6. ULURU Inc. Reports Second Quarter 2010 Financial Results
7. ULURU Inc. Invited to Present Altrazeal(TM) Research at 10th Annual Wound Healing Science and Industry Conference
8. ULURU Inc. Obtains Status of Approved Supplier With McKesson.
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
10. ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... YORK , Dec. 7, 2016 ... report on pulmonary drugs studies the current as ... The stakeholders of this report include companies and ... various pulmonary/respiratory drugs and/or drug-device combinations as well ... This report comprises an elaborate executive summary along ...
(Date:12/7/2016)... , Dec. 7, 2016  The Corporate Whistleblower ... manager to call them anytime at 866-714-6466 if they ... to sell more drugs. Aside from the innocent patients ... as well, because often-times these practices target Medicare recipients or ... ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
Breaking Medicine Technology:
(Date:12/7/2016)... Honolulu, HI (PRWEB) , ... December 07, 2016 ... ... Dermatology is proud to announce that its fully redesigned website, which launched October ... well as a sleek responsive design and easy-to-navigate layout. Visitors and patients can ...
(Date:12/7/2016)... ... 2016 , ... Texas Premier Locksmith , a leading ... unethical locksmith companies and is urging Search Engines to improve verification methods in ... Locksmith, these fraudulent locksmith services take advantage of consumers locked out of houses, ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX ... media," said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes ... use drop zones. Editors can select from a variety of flip book animations. In ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, ... at Reproductive Medicine Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of ... acupuncturists to help patients realize their family building goals. Acupuncture helps fertility ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons from My Life's ... reader to be aware of God's direction in their lives. “Walking With God: Inspirational ... teacher and active church leader. , Sanford says, “I enjoy sharing the ...
Breaking Medicine News(10 mins):